General Information of the Compound
Compound ID
CP0217203
Compound Name
GS-4997
    Show/Hide
Synonyms
GS-4997
    Show/Hide
Structure
Formula
C24H24FN7O
Molecular Weight
445.502
Canonical SMILES
CC(C)n1cnnc1-c1cccc(NC(=O)c2cc(c(C)cc2F)-n2cnc(c2)C2CC2)n1
    Show/Hide
InChI
InChI=1S/C24H24FN7O/c1-14(2)32-13-27-30-23(32)19-5-4-6-22(28-19)29-24(33)17-10-21(15(3)9-18(17)25)31-11-20(26-12-31)16-7-8-16/h4-6,9-14,16H,7-8H2,1-3H3,(H,28,29,33)
    Show/Hide
InChIKey
YIDDLAAKOYYGJG-UHFFFAOYSA-N
CAS
1448428-04-3
Physicochemical Property
logP
4.68392
Rotatable Bonds
6
Heavy Atom Count
33
Polar Areas
90.52
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
7
Complexity
33

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 71245288
SID: 163506108
ChEMBL ID
CHEMBL3916717
DrugBank ID
DB14916
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01533, Mitogen-activated protein kinase kinase kinase 5
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000012 Sf21 Spodoptera frugiperda (Fall armyworm)  1
1
IC50 = 5.012 nM
   TI
   LI
   LO
   TS
CL000025 HEK-293T Homo sapiens (Human)  1
1
IC50 = 20 nM
   TI
   LI
   LO
   TS
CL000006 HEK293 Homo sapiens (Human)  1
1
IC50 = 7501 nM
   TI
   LI
   LO
   TS
Biochemical Assays
1 IC50 = 3 nM
2 IC50 = 5 nM
3 IC50 = 5.5 nM
4 IC50 = 5.9 nM
5 IC50 = 6 nM
6 IC50 = 12.9 nM
7 IC50 = 24.4 nM
Clinical Information about the Compound
Drug 1 ( GS-4997 )
Drug Name GS-4997
Indication
Diabetic nephropathy
Phase 2
Pulmonary arterial hypertension
Phase 2
Target(s)
Apoptosis signal-regulating kinase 1 (MAP3K5)
Inhibitor